Oragenics closes $2.1M public offering of 1.4M shares; funds ONP-002 development

ORAGENICS INC

Issued 1,400,000 shares at $1.50/share for gross proceeds of $2.1M.
Underwriters granted a 45-day option for up to 210,000 additional shares.
Net proceeds to fund continued development of ONP-002 for concussion treatment.
Representative's warrants issued for up to 5% of Shares at $1.875/share.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ORAGENICS INC entered into Underwriting Agreement with ThinkEquity LLC valued at $2.1 million (effective 2024-02-27).

Action: entry
Agreement: underwriting
Counterparty: ThinkEquity LLC
Value: $2.1 million
Effective: 2024-02-27

Exact text from the filing

On February 27, 2024, Oragenics, Inc. (“Oragenics” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as representative (the “Representative”) of the underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 1,400,000 shares of the Company’s common stock at a price to the public of $1.50 per share (the “Underwritten Shares”).

View on SEC.gov

Browse all material agreements →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-24-008489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.